A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 211
- 试验地点
- 1
- 主要终点
- Overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide, who have previously undergone treatment with chemotherapy (docetaxel)
研究概览
简要总结
The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.
The primary purpose is to evaluate overall survival (OS) in mCRPC patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel) (post chemo patients).
This study will also evaluate treatment duration with enzalutamide in patients pre- and post-chemo.
详细描述
The data source in this study is a local hospital registry created from a patient follow up of prostate cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
enzalutamide (mCRPC pre-chemo)
Patients treated with enzalutamide prior to chemotherapy
干预措施: enzalutamide (Drug)
enzalutamide and chemotherapy (mCRPC post chemo)
Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
干预措施: enzalutamide (Drug)
enzalutamide and chemotherapy (mCRPC post chemo)
Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
干预措施: docetaxel (Drug)
结局指标
主要结局
Overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide, who have previously undergone treatment with chemotherapy (docetaxel)
时间窗: Up to a maximum of four years
Overall survival is defined as time from initiation to death of any cause.
次要结局
- Treatment duration of enzalutamide in post chemo mCRPC patients(Up to a maximum of four years)
- Treatment duration of enzalutamide in pre chemo mCRPC patients(Up to a maximum of four years)